{"id":"NCT02593773","sponsor":"Amgen","briefTitle":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study","officialTitle":"Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-25","primaryCompletion":"2017-03-21","completion":"2017-03-21","firstPosted":"2015-11-02","resultsPosted":"2018-05-18","lastUpdate":"2024-12-19"},"enrollment":86,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Friedreich's Ataxia"],"interventions":[{"type":"DRUG","name":"Interferon γ-1b","otherNames":["ACTIMMUNE®"]}],"arms":[{"label":"interferon γ-1b","type":"EXPERIMENTAL"}],"summary":"The purpose of this phase 3 multi-center, open-label extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs","timeFrame":"Baseline/Day 1 (Week 26 of Study HZNP-ACT-301 [NCT02415127]) through Week 28 (follow-up safety visit)","effectByArm":[{"arm":"Interferon γ-1b","deltaMin":78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":86},"commonTop":["Headache","Neutropenia","Pyrexia","Nausea","Vomiting"]}}